Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation

Mark J. Alberts, John W. Eikelboom, Graeme J. Hankey

Research output: Contribution to journalReview article

70 Scopus citations

Abstract

The world faces an epidemic of atrial fibrillation and atrial fibrillation-related stroke. An individual's risk of atrial fibrillation-related stroke can be estimated with the CHADS2 or CHA2DS2VASc scores, and reduced by two-thirds with effective anticoagulation. Vitamin K antagonists, such as warfarin, are underused and often poorly managed. The direct thrombin inhibitor dabigatran etexilate and factor Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least as efficacious and safe as warfarin. Their advantages are predictable anticoagulant effects, low propensity for drug interactions, and lower rates of intracranial haemorrhage than with warfarin. A disadvantage is the continuing need to develop and validate rapidly effective antidotes for major bleeding and standardised tests that accurately measure plasma concentrations and anticoagulant effects, together with the disadvantage of possible higher rates of gastrointestinal haemorrhage and greater expense than with warfarin. The new oral anticoagulants should increase the number of patients with atrial fibrillation at risk of stroke who are optimally anticoagulated, and reduce the burden of atrial fibrillation-related stroke.

Original languageEnglish (US)
Pages (from-to)1066-1081
Number of pages16
JournalThe Lancet Neurology
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation'. Together they form a unique fingerprint.

  • Cite this